phone icon
+44 (0)1223 298875

Anti-RUNX1 / AML1 Antibody (Biotin)

FabGennix
RUNX1-BIOTIN
Details
Description: Rabbit polyclonal antibody to RUNX1 / AML1 (Biotin)
Category: Primary Antibodies
Applications: ELISA, WB
Host: Rabbit
Clonality: Polyclonal
Conjugate: Biotin
Reactivity: Bovine, Human, Monkey
UniProt: Q01196
Immunogen: Synthetic peptide taken within amino acid region 1-80 on human RUNX1 protein.
Concentration: 0.51-0.53 µg/µl in antibody stabilization buffer
Synonyms: Acute myeloid leukemia 1 protein antibody
Background: CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis.
Storage: -20⁰C for long term storage
Accession No: AAI36381
Recommended Dilutions: W: 1:10,000; ELISA: 1:10,000; Western Blot: 1:500

Target (Information from UniProt)
Function: CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B-dependent transcriptional activation. Controls the anergy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. Activates the expression of IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells (PubMed:17377532).
Tissue Specificity: Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood.
Involvement in Disease: Familial platelet disorder with associated myeloid malignancy: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.
Post-Translational Modification: Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with KAT6A.
Cellular Location: Nucleus.

Product Code - RUNX1-BIOTIN
Size Price Quantity
100µg £429

or
Request a quotation
Contact us directly to order
  • call icon +44 (0)1223 298875
  • +44 (0)1223 281447
  • email icon orders@ab-y-ss.com
Product Quality
  • guarantee icon
  • We promise guaranteed product quality
  • and expert customer service.
Shipping Information
  • £20 to United Kingdom
  • £35 to Europe